John A. Ellerton
Expertise in
7
conditions

Dr. John A. Ellerton

Hematology | Oncology
6190 S Fort Apache Rd, 
Las Vegas, NV 
Accepting New Patients
Referral required
Before you request
Expertise in
7
conditions
6190 S Fort Apache Rd, 
Las Vegas, NV 

Overview

John Ellerton is a Hematologist and an Oncologist practicing medicine in Las Vegas, Nevada.

Dr. Ellerton is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Breast Cancer, Hairy Cell Leukemia (HCL), Tissue Biopsy, and Bone Marrow Aspiration.

Dr. Ellerton is board certified in Internal Medicine (Sub: Medical Oncology), Internal Medicine (Sub: Hospice And Palliative Medici, Internal Medicine (Sub: Hematology), American Board Of Internal Medicine, and Internal Medicine. He is actively involved in clinical research, co-authoring 5 peer reviewed articles and participating in 157 clinical trials. Dr. Ellerton is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in NV

Board Certifications

Internal Medicine (Sub: Medical Oncology)
Internal Medicine (Sub: Hospice And Palliative Medici
Internal Medicine (Sub: Hematology)
American Board Of Internal Medicine
Internal Medicine

Hospital Affiliations

Centennial Hills Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

OptumCare Cancer Care
6190 S Fort Apache Rd, Las Vegas, NV 89148

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

157 Clinical Trials

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Trametinib
Study Phase: Phase 2
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other, Procedure
Study Phase: Phase 3
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other
Study Phase: Early Phase 1
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Enrollment Status: Suspended
Publish Date: September 04, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2/Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)
A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)
Enrollment Status: Active_not_recruiting
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug
Study Drug: AKR1C3-Activated Prodrug OBI-3424
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

5 Total Publications

OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer.
OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer.
Journal: Breast cancer research and treatment
Published: January 05, 2026
Similar Doctors
Expertise in
40
conditions
Dr. Hamdy A. Mohtaseb
Hematology | Oncology
Expertise in
40
conditions
Dr. Hamdy A. Mohtaseb
Hematology | Oncology
Referral may be required

Arthritis Associates Of Nevada

8905 S Pecos Rd Ste 23A, 
Henderson, NV 
 (11.4 miles away)
702-361-3030
Languages Spoken:
English, Spanish
See accepted insurances
Offers Telehealth

Hamdy Mohtaseb is a Hematologist and an Oncologist practicing medicine in Henderson, Nevada. Dr. Mohtaseb is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Monoclonal Gammopathy of Undetermined Significance (MGUS), Colorectal Cancer, Polycythemia Vera, and Anemia.

Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Comprehensive Cancer Centers Of Nevada

3730 S Eastern Ave, 
Las Vegas, NV 
 (10.5 miles away)
702-952-3400
Languages Spoken:
English
See accepted insurances

Nicholas Vogelzang is an Oncologist practicing medicine in Las Vegas, Nevada. Dr. Vogelzang is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Urothelial Cancer, Orchiectomy, and Nephrectomy.

Expertise in
2
conditions
Dr. Michael D. Becker
Hematology | Oncology
Expertise in
2
conditions
Dr. Michael D. Becker
Hematology | Oncology
Referral may be required
Before you request

Optum Cancer Care

3980 S Eastern Ave, 
Las Vegas, NV 
 (10.4 miles away)
702-463-9100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Becker is a Hematologist and an Oncologist practicing medicine in Las Vegas, Nevada. Dr. Becker is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, and Choriocarcinoma. Dr. Becker is board certified in American Board Of Radiology. Dr. Becker is currently accepting new patients.

Frequently Asked Questions about Dr. John A. Ellerton

How do I make an appointment with Dr. John A. Ellerton?

You can book an appointment with Dr. John A. Ellerton by calling their office at 702-724-8787. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. John A. Ellerton a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John A. Ellerton is classified as an Advanced expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John A. Ellerton specialize in?

While Dr. John A. Ellerton is a Hematology, they have specific expertise in Colorectal Cancer, Breast Cancer, and Hairy Cell Leukemia (HCL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. John A. Ellerton participate in research or clinical trials?

Yes. Dr. John A. Ellerton has published 5 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. John A. Ellerton's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. John A. Ellerton accept my insurance?

Dr. John A. Ellerton accepts most major insurance plans, including Aetna and Cigna. We recommend calling the office directly at 702-724-8787 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ellerton's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 117 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile